Experience with siponimod for treating patients with secondary progressive multiple sclerosis in the Moscow Region
Siponimod is a sphingosine-1-phosphate receptor modulator approved in most countries for the treatment of secondary progressive multiple sclerosis (SPMS) with activity. The EXPAND study showed that the drug effectively reduces disease activity at the peripheral level by preventing autoreactive immun...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
IMA-PRESS LLC
2025-12-01
|
| Col·lecció: | Неврология, нейропсихиатрия, психосоматика |
| Matèries: | |
| Accés en línia: | https://nnp.ima-press.net/nnp/article/view/2740 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|